


# Colombia - BCG




## Description:

- 1997: Legacy estimate.
- 1998: Reported data (85 percent) calibrated to 1997 and 1999 levels.
- 1999: Survey confirms high levels of coverage and supports nationally reported data for other antigens.
- 2000: Estimate based on reported data.
- 2001: Estimate based on reported data.
- 2002: Estimate based on reported data.
- 2003: Estimate based on reported data.
- 2004: Estimate based on reported data (92 percent) confirmed by survey (97 percent).
- 2005: Estimate based on reported data.
- 2006: Estimate based on reported data.
- 2007: Estimate based on reported data.
- 2008: Estimate based on reported data.
- 2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	97	85	80	91	87	87	97	92	94	96	93	93	90
Reported	98	85	80	91	87	87	97	92	94	96	93	93	90
Official	98	85	80	91	87	87	97	92	94	96	93	93	90
Administrative	98	85	80	91	87	87	97	92	94	96	93	93	90
Survey	NA	NA	93	NA	NA	NA	NA	97	NA	NA	NA	NA	NA

# Colombia - DTP1




## Description:

- 1997: Legacy estimate.
- 1998: Estimate interpolated between 1997 and 1999 estimates.
- 1999: Estimate based on survey results. Reported data (75 percent) not consistent with survey results (95 percent).
- 2000: Estimate interpolated between 1999 and 2004 estimates.
- 2001: Estimate interpolated between 1999 and 2004 estimates.
- 2002: Estimate interpolated between 1999 and 2004 estimates.
- 2003: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.
- 2004: Estimate based on interpolated value between reported data. Survey (97 percent) confirms trend in reported data.
- 2005: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.
- 2006: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.
- 2007: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.
- 2008: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.
- 2009: Estimated DTP3 greater than estimated DTP1; DTP1 estimate based on the relationship between DTP1 and DTP3 from 282 surveys.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	94	95	95	94	93	91	97	89	97	97	97	97	97
Reported	NA	NA	NA	75	74	NA	91	NA	86	85	91	90	91
Official	NA	NA	NA	75	NA	NA	NA	NA	86	85	91	90	91
Administrative	NA	NA	NA	75	74	NA	91	NA	86	85	91	90	91
Survey	NA	NA	95	NA	NA	NA	NA	97	NA	NA	NA	NA	NA

# Colombia - DTP3



## Description:

1997: Legacy estimate.

1998: Estimate based on reported data.

1999: Estimate based on reported data (74 percent) confirmed by survey (82 percent). Survey results (77 percent) adjusted for recall bias to 82 percent based on first dose card or history coverage (95 percent) and documented drop-out between first (73 percent) and third (63 percent) doses.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data.

2003: Estimate based on reported data.

2004: Estimate based on reported data (89 percent) confirmed by survey (89 percent). Survey results (81 percent) adjusted for recall bias to 89 percent based on first dose card or history coverage (97 percent) and documented drop-out between first (77 percent) and third (71 percent) doses.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data.


2008: Estimate based on reported data.

2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	84	73	74	79	80	81	92	89	93	93	93	92	92
Reported	84	73	74	79	80	81	92	89	93	93	93	92	92
Official	84	73	74	79	80	81	92	89	93	93	93	92	92
Administrative	84	73	74	79	80	81	92	89	93	93	93	92	92
Survey	NA	NA	82	NA	NA	NA	NA	89	NA	NA	NA	NA	NA

# Colombia - Pol3

## Description:



1997: Legacy estimate.

1998: Estimate based on reported data.

1999: Estimate based on reported data (77 percent) confirmed by survey (81 percent). Survey results (71 percent) adjusted for recall bias to 81 percent based on first dose card or history coverage (97 percent) and documented drop-out between first (74 percent) and third (62 percent) doses.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data.

2003: Estimate based on reported data.

2004: Estimate based on reported data. Survey results of 69 percent ignored by working group. Polio results inconsistent with other vaccines. Polio birth dose may have been recorded as first recommended dose.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data.


2008: Estimate based on reported data.

2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	85	75	77	82	83	83	92	89	93	94	93	92	92
Reported	85	75	77	82	83	83	92	89	93	94	93	92	92
Official	85	75	77	82	83	83	92	89	93	94	93	92	92
Administrative	85	75	77	82	83	83	92	89	93	94	93	92	92
Survey	NA	NA	81	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

# Colombia - MCV

COL - MCV



	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	88	78	77	80	88	93	93	92	94	95	95	92	95
Reported	88	78	77	80	88	93	93	92	94	95	95	92	95
Official	88	78	77	80	88	93	93	92	94	95	95	92	95
Administrative	88	78	77	80	88	93	93	92	94	95	95	92	95
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

## Description:

1997: Legacy estimate.

1998: Estimate based on reported data.

1999: Estimate based on reported data. Survey results of 71 percent ignored by working group. Measles vaccination is recommend between 12-23 months of age. Survey cohort underestimates coverage.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data.

2003: Estimate based on reported data.

2004: Estimate based on reported data. Survey results of 82 percent ignored by working group. Measles vaccination is recommend between 12-23 months of age. Survey cohort underestimates coverage.

2005: Estimate based on reported data.

2006: Estimate based on reported data.


2007: Estimate based on reported data.

2008: Estimate based on reported data.

2009: Estimate based on reported data.

# Colombia - HepB3


## Description:



1997: Legacy estimate.  
 1998: Estimate based on reported data.  
 1999: Estimate based on reported data (77 percent) confirmed by survey (77 percent).  
 2000: Estimate based on reported data.  
 2001: Estimate based on reported data.  
 2002: Estimate based on reported data.  
 2003: Estimate based on reported data.  
 2004: Estimate based on reported data.  
 2005: Estimate based on reported data.  
 2006: Estimate based on reported data.  
 2007: Estimate based on reported data.  
 2008: Estimate based on reported data.  
 2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	85	75	77	78	80	78	92	89	93	93	93	92	92
Reported	85	75	77	78	80	78	92	89	93	93	93	92	92
Official	85	75	77	78	80	78	92	89	93	93	93	92	92
Administrative	85	75	77	78	80	78	92	89	93	93	93	92	92
Survey	NA	NA	77	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

# Colombia - Hib3



## Description:

1998: Estimate based on reported data. Hib introduced in 1998 Vaccine presentation is DTP-HepB-Hib.

1999: Estimate based on reported data. Missing or ignored reported value estimated by interpolation between reported values of 62 percent in 1998 and 65 percent in 2000. 1999 reported data (50 percent) inconsistent with data from other years.

2000: Estimate based on reported data.

2001: Estimate based on reported data.

2002: Estimate based on reported data.

2003: Estimate based on reported data.

2004: Estimate based on reported data.

2005: Estimate based on reported data.

2006: Estimate based on reported data.

2007: Estimate based on reported data.

2008: Estimate based on reported data.


2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	NA	62	64	65	55	69	93	89	93	93	93	92	92
Reported	NA	62	50	65	55	69	93	89	93	93	93	92	92
Official	NA	62	50	65	55	69	93	89	93	93	93	92	92
Administrative	NA	62	50	65	55	69	93	89	93	93	93	92	92
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

# Colombia - RotaC


## Description:

2009: Estimate based on reported data. Rotavirus vaccine introduced in 2009.



	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	82
Reported	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	82
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	82
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	82
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA


# Colombia - PnV3



	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Reported	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

# Colombia - YFV

COL - YFV



## Description:

2006: Estimate based on reported data. YFV introduced in 2003 reporting started in 2006  
 2007: Estimate based on reported data.  
 2008: Estimate based on reported data. Decline attributed to vaccine shortage.  
 2009: Estimate based on reported data.

	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	88	84	81	95
Reported	NA	NA	NA	NA	NA	NA	NA	NA	NA	88	84	81	95
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	88	84	81	95
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	88	84	81	95
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

# Colombia - survey details

## 2004 Salud sexual y reproductiva en Colombia, Encuesta nacional de demografía y salud 2005

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	C or H <12 months	96	12-23 m	2705	78
BCG	Card	76	12-23 m	2705	78
BCG	Card or History	97	12-23 m	2705	78
BCG	History	20	12-23 m	2705	78
DTP1	C or H <12 months	96	12-23 m	2705	78
DTP1	Card	77	12-23 m	2705	78
DTP1	Card or History	97	12-23 m	2705	78
DTP1	History	20	12-23 m	2705	78
DTP3	Card or History	81	12-23 m	2705	78
DTP3	Card	71	12-23 m	2705	78
DTP3	History	10	12-23 m	2705	78
DTP3	C or H <12 months	76	12-23 m	2705	78
MCV	Card	65	12-23 m	2705	78
MCV	Card or History	82	12-23 m	2705	78
MCV	History	17	12-23 m	2705	78
MCV	C or H <12 months	52	12-23 m	2705	78
Pol1	Card or History	89	12-23 m	2705	78
Pol1	History	18	12-23 m	2705	78
Pol1	Card	71	12-23 m	2705	78
Pol1	C or H <12 months	88	12-23 m	2705	78
Pol3	Card	64	12-23 m	2705	78
Pol3	Card or History	69	12-23 m	2705	78
Pol3	History	5	12-23 m	2705	78
Pol3	C or H <12 months	65	12-23 m	2705	78

## 1999 Salud Sexual y Reproductiva en Colombia, Resultados Encuesta Nacional de Demografía y Salud 2000

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	Card or History	93	12-23 m	890	75
BCG	C or H <12 months	92	12-23 m	890	75

BCG	History	23	12-23 m	890	75
BCG	Card	70	12-23 m	890	75
BCG	C or H <12 months	92	24-35 m	894	63
BCG	C or H <12 months	93	36-47 m	848	62
BCG	C or H <12 months	93	48-59 m	888	57
DTP1	Card or History	95	12-23 m	890	75
DTP1	History	22	12-23 m	890	75
DTP1	Card	73	12-23 m	890	75
DTP1	C or H <12 months	93	12-23 m	890	75
DTP1	C or H <12 months	94	24-35 m	894	63
DTP1	C or H <12 months	93	36-47 m	848	62
DTP1	C or H <12 months	93	48-59 m	888	57
DTP3	C or H <12 months	67	12-23 m	890	75
DTP3	History	13	12-23 m	890	75
DTP3	Card or History	77	12-23 m	890	75
DTP3	Card	63	12-23 m	890	75
DTP3	C or H <12 months	71	24-35 m	894	63
DTP3	C or H <12 months	74	36-47 m	848	62
DTP3	C or H <12 months	74	48-59 m	888	57
HepB3	Card or History	77	12-23 m	890	75
MCV	History	19	12-23 m	890	75
MCV	Card or History	71	12-23 m	890	75
MCV	Card	52	12-23 m	890	75
Pol1	History	24	12-23 m	890	75
Pol1	C or H <12 months	95	12-23 m	890	75
Pol1	Card	74	12-23 m	890	75
Pol1	Card or History	97	12-23 m	890	75
Pol1	C or H <12 months	94	24-35 m	894	63
Pol1	C or H <12 months	94	36-47 m	848	62
Pol1	C or H <12 months	94	48-59 m	888	57
Pol3	Card	62	12-23 m	890	75
Pol3	Card or History	71	12-23 m	890	75
Pol3	History	9	12-23 m	890	75
Pol3	C or H <12 months	63	12-23 m	890	75
Pol3	C or H <12 months	60	24-35 m	894	63
Pol3	C or H <12 months	63	36-47 m	848	62
Pol3	C or H <12 months	65	48-59 m	888	57

# Colombia - survey details

---

Further information and estimates for 1980-1996 are available at:

[http://www.childinfo.org/immunization\\_countryreports.html](http://www.childinfo.org/immunization_countryreports.html)

[http://www.who.int/immunization\\_monitoring/routine/immunization\\_coverage/en/index4.html](http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html)

## Colombia

### WHO/UNICEF Estimates of Protection at Birth (PAB) against tetanus

In countries where tetanus is recommended for girls and women coverage is usually reported as "TT2+", i.e. the proportion of (pregnant) women who have received their second or superior TT dose in a given year. TT2 + coverage, however, can under-represent the actual proportion of births that are protected against tetanus as it does not include women who have previously received protective doses, women who received one dose without documentation of previous doses, and women who received doses in TT (or Td) supplemental immunization activities (SIA). In addition, girls who have received DTP in their childhood and are entering childbearing age, may be protected with TT booster doses.

WHO and UNICEF have developed a model that takes into account the above scenarios, and calculates the proportion of births in a given year that can be considered as having been protected against tetanus - "Protection at Birth".

In this model, annual cohorts of women are followed from infancy through their life. A proportion receive DTP in infancy (estimated based on the WHO-UNICEF estimates of DTP3 coverage). In addition some of these women also receive TT through routine services when they are pregnant and may also receive TT during SIAs. The model also adjusts reported data, taking into account coverage patterns in other years, and/or results available through surveys. The duration of protection is then calculated, based on WHO estimates of the duration of protection by doses ever received. The proportion of births that are protected against tetanus as a result of maternal immunization reflects the tetanus immunization received by the mother throughout her life rather than simply the TT immunizations received during the current pregnancy.

Year	PAB coverage estimate (%)
1997	66
1998	67
1999	69
2000	70
2001	71
2002	72
2003	73
2004	76
2005	77
2006	77
2007	78
2008	78
2009	78

---

<sup>1</sup> This model is described in: Griffiths U., Wolfson L., Quddus A., Younus M., Hafiz R.. Incremental cost-effectiveness of supplementary immunization activities to prevent neo-natal tetanus in Pakistan. Bulletin of the World Health Organization 2004; 82:643-651.